Walleye Capital
MYGN icon

Walleye Capital’s Myriad Genetics MYGN Stock Holding History

Walleye Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,300
Closed -$45.5K – 4944
2025
Q3 		$45.5K Sell
6,300
-19,000
-75% -$113K ﹤0.01% 4031
2025
Q2 		$134K Buy
+25,300
New +$149K ﹤0.01% 3619
2024
Q1 		– Sell
-2,000
Closed -$38.3K – 5719
2023
Q4 		$38.3K Sell
2,000
-8,200
-80% -$142K ﹤0.01% 4363
2023
Q3 		$164K Buy
+10,200
New +$194K ﹤0.01% 3690
2020
Q1 		– Sell
-5,700
Closed -$155K – 1413
2019
Q4 		$155K Sell
5,700
-21,800
-79% -$600K 0.01% 1222
2019
Q3 		$787K Buy
+27,500
New +$801K 0.05% 546
2019
Q2 		– Sell
-11,200
Closed -$372K – 1930
2019
Q1 		$372K Buy
+11,200
New +$341K 0.06% 504

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's MYGN Position: Q1 2026 in Review

Walleye Capital sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 677,176 shares — an estimated $4.16M sold.

Walleye Capital first reported a position in MYGN in Q1 2019 and held it in 17 quarters. The position peaked at $4.16M in Q4 2025. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Walleye Capital reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 677,176 Myriad Genetics shares in Q1 2026, an estimated $4.16M.
  • Walleye Capital first reported a position in Myriad Genetics in Q1 2019 and held it in 17 quarters.
  • Walleye Capital's Myriad Genetics position peaked at $4.16M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.